Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 340

1.

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.

Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland JGF, Damman K, Redon J, Coats AJS; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2019 Dec 10;74(23):2893-2904. doi: 10.1016/j.jacc.2019.09.059.

2.

Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure.

Dobre D, Kjekshus J, Rossignol P, Girerd N, Benetos A, Dickstein K, Zannad F.

Int J Cardiol. 2018 Nov 15;271:181-185. doi: 10.1016/j.ijcard.2018.05.017.

PMID:
30223350
3.

Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.

Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R.

Eur J Heart Fail. 2018 May;20(5):888-895. doi: 10.1002/ejhf.1146. Epub 2018 Feb 28.

4.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.

Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group.

Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564.

5.

Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative.

Agewall S, Tjessem LH, Rossignol P, Zannad F, Atar D, Lamiral Z, Machu JL, Dickstein K, Kjekshus J, von Lueder TG, Girerd N; High Risk Myocardial Infarction Database Initiative investigators.

Int J Cardiol. 2017 Dec 15;249:274-281. doi: 10.1016/j.ijcard.2017.09.182. Epub 2017 Sep 24.

PMID:
28964557
6.

Declining Risk of Sudden Death in Heart Failure.

Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV.

N Engl J Med. 2017 Jul 6;377(1):41-51. doi: 10.1056/NEJMoa1609758.

7.

A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database.

Tajik AA, Dobre D, Aguilar D, Kjekshus J, Zannad F, Dickstein K; High-Risk MI Database Scientific Committee.

Eur J Heart Fail. 2017 May;19(5):635-642. doi: 10.1002/ejhf.797.

8.

Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.

Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2017 Jun 20;69(24):2885-2896. doi: 10.1016/j.jacc.2017.04.001. Epub 2017 Apr 30. Review.

9.

Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure.

Nymo SH, Aukrust P, Kjekshus J, McMurray JJ, Cleland JG, Wikstrand J, Muntendam P, Wienhues-Thelen U, Latini R, Askevold ET, Gravning J, Dahl CP, Broch K, Yndestad A, Gullestad L, Ueland T; CORONA Study Group.

JACC Heart Fail. 2017 Apr;5(4):256-264. doi: 10.1016/j.jchf.2017.01.008.

10.

High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction.

Ellingsen Ø, Halle M, Conraads V, Støylen A, Dalen H, Delagardelle C, Larsen AI, Hole T, Mezzani A, Van Craenenbroeck EM, Videm V, Beckers P, Christle JW, Winzer E, Mangner N, Woitek F, Höllriegel R, Pressler A, Monk-Hansen T, Snoer M, Feiereisen P, Valborgland T, Kjekshus J, Hambrecht R, Gielen S, Karlsen T, Prescott E, Linke A; SMARTEX Heart Failure Study (Study of Myocardial Recovery After Exercise Training in Heart Failure) Group.

Circulation. 2017 Feb 28;135(9):839-849. doi: 10.1161/CIRCULATIONAHA.116.022924. Epub 2017 Jan 12.

11.

Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA).

Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P, Ueland T.

Biomarkers. 2017 May - Jun;22(3-4):261-267. doi: 10.1080/1354750X.2016.1204003. Epub 2016 Jul 12.

12.

Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.

Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, Waagstein F, McMurray JJ.

Eur J Heart Fail. 2016 Mar;18(3):328-36. doi: 10.1002/ejhf.462. Epub 2015 Dec 23.

13.

Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.".

Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR, McMurray JJ.

Circulation. 2015 Dec 1;132(22):e358. doi: 10.1161/CIRCULATIONAHA.115.018395. No abstract available.

PMID:
26621661
14.

Inflammation: Friend and Foe.

Kjekshus J.

EBioMedicine. 2015 Jun 3;2(7):634-5. doi: 10.1016/j.ebiom.2015.05.029. eCollection 2015 Jul. No abstract available.

15.

Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, Cleland JG, McMurray JJ, Aukrust P, Ueland T.

PLoS One. 2015 Aug 19;10(8):e0133970. doi: 10.1371/journal.pone.0133970. eCollection 2015.

16.

Are statins failing in heart failure?

Kjekshus J.

Eur Heart J. 2015 Jun 21;36(24):1502-4. doi: 10.1093/eurheartj/ehv133. Epub 2015 Apr 16. No abstract available.

PMID:
25883176
17.

Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.

Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR, McMurray JJ; Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA); GISSI-Heart Failure (GISSI-HF) Committees and Investigators.

Circulation. 2015 Apr 28;131(17):1486-94; discussion 1494. doi: 10.1161/CIRCULATIONAHA.114.013760. Epub 2015 Mar 25.

PMID:
25810334
18.

Sensitive cardiac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery disease: correlation with left ventricular function as assessed by myocardial strain.

Smedsrud MK, Gravning J, Omland T, Eek C, Mørkrid L, Skulstad H, Aaberge L, Bendz B, Kjekshus J, Edvardsen T.

Int J Cardiovasc Imaging. 2015 Jun;31(5):967-73. doi: 10.1007/s10554-015-0646-6. Epub 2015 Mar 19.

PMID:
25788439
19.

Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.

Kristensen SL, Jhund PS, Køber L, Preiss D, Kjekshus J, McKelvie RS, Zile MR, Anand IS, Wikstrand J, Wedel H, Komajda M, Carson PE, Cleland JG, McMurray JJ.

Eur J Heart Fail. 2015 Feb;17(2):169-76. doi: 10.1002/ejhf.211. Epub 2014 Dec 30.

20.

Exercise-induced vasodilation in healthy males: A marker of reduced endothelial function.

Wethal T, Røysland R, Torbjørn O, Kjekshus J.

Scand Cardiovasc J. 2015 Jun;49(3):123-9. doi: 10.3109/14017431.2015.1021708. Epub 2015 May 6.

PMID:
25752356
21.

Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF.

Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, Kjekshus J, Tavazzi L, McMurray J, Lloyd-Jones DM.

Eur J Heart Fail. 2015 Apr;17(4):434-41. doi: 10.1002/ejhf.247. Epub 2015 Feb 14.

22.

Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA).

Haver VG, Mateo Leach I, Kjekshus J, Fox JC, Wedel H, Wikstrand J, de Boer RA, van Gilst WH, McMurray JJ, van Veldhuisen DJ, van der Harst P.

Eur J Heart Fail. 2015 Mar;17(3):313-9. doi: 10.1002/ejhf.237. Epub 2015 Feb 2.

23.

The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA).

Haver VG, Verweij N, Kjekshus J, Fox JC, Wedel H, Wikstrand J, van Gilst WH, de Boer RA, van Veldhuisen DJ, van der Harst P.

BMC Med Genet. 2014 Dec 21;15:140. doi: 10.1186/s12881-014-0140-3.

24.

Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.

Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Block D, Zaugg C, Gullestad L.

J Card Fail. 2015 Feb;21(2):153-9. doi: 10.1016/j.cardfail.2014.10.016. Epub 2014 Nov 7.

PMID:
25451704
25.

Predictive value of endostatin in chronic heart failure patients with poor kidney function.

Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Wienhues-Thelen UH, Block D, Zaugg C, Gullestad L.

Cardiology. 2015;130(1):17-22. doi: 10.1159/000368220. Epub 2014 Nov 22.

PMID:
25428583
26.

International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.

Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, Zile MR, Granger CB, Wikstrand J, Komajda M, Carson PE, Pfeffer MA, Swedberg K, Wedel H, Yusuf S, McMurray JJ.

Circulation. 2015 Jan 6;131(1):43-53. doi: 10.1161/CIRCULATIONAHA.114.012284. Epub 2014 Nov 18.

PMID:
25406306
27.

Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Badar AA, Perez-Moreno AC, Jhund PS, Wong CM, Hawkins NM, Cleland JG, van Veldhuisen DJ, Wikstrand J, Kjekshus J, Wedel H, Watkins S, Gardner RS, Petrie MC, McMurray JJ.

Eur Heart J. 2014 Dec 21;35(48):3426-33. doi: 10.1093/eurheartj/ehu342. Epub 2014 Sep 28.

PMID:
25265976
28.

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N.

Lancet. 2015 Jan 24;385(9965):351-61. doi: 10.1016/S0140-6736(14)61183-1. Epub 2014 Sep 24.

29.

Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).

Rogers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ.

JACC Heart Fail. 2014 Jun;2(3):289-97. doi: 10.1016/j.jchf.2013.12.007. Epub 2014 Apr 30.

30.

Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).

Perez-Moreno AC, Jhund PS, Macdonald MR, Petrie MC, Cleland JG, Böhm M, van Veldhuisen DJ, Gullestad L, Wikstrand J, Kjekshus J, Lewsey JD, McMurray JJ.

JACC Heart Fail. 2014 Apr;2(2):187-97. doi: 10.1016/j.jchf.2014.01.001.

31.

Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure).

Perez AC, Jhund PS, Stott DJ, Gullestad L, Cleland JG, van Veldhuisen DJ, Wikstrand J, Kjekshus J, McMurray JJ.

JACC Heart Fail. 2014 Feb;2(1):35-40. doi: 10.1016/j.jchf.2013.07.008. Epub 2014 Jan 25.

32.

The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction.

Ketchum ES, Dickstein K, Kjekshus J, Pitt B, Wong MF, Linker DT, Levy WC.

Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):46-55. doi: 10.1177/2048872613502283. Epub 2013 Sep 11.

33.

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.

Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J; CORONA Study Group.

Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. Epub 2013 Nov 27.

PMID:
24284025
34.

Atherosclerotic lesions in lymphoma survivors treated with radiotherapy.

Wethal T, Nedregaard B, Andersen R, Fosså A, Lund MB, Günther A, Kvaløy S, Fosså SD, Kjekshus J.

Radiother Oncol. 2014 Mar;110(3):448-54. doi: 10.1016/j.radonc.2013.10.029. Epub 2013 Nov 11.

PMID:
24231235
35.

An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.

Batty JA, Hall AS, White HL, Wikstrand J, de Boer RA, van Veldhuisen DJ, van der Harst P, Waagstein F, Hjalmarson Å, Kjekshus J, Balmforth AJ; MERIT-HF Study Group.

Clin Pharmacol Ther. 2014 Mar;95(3):321-30. doi: 10.1038/clpt.2013.193. Epub 2013 Sep 30.

PMID:
24193112
36.

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL; ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG.

Eur Heart J. 2013 Oct;34(39):3035-87. doi: 10.1093/eurheartj/eht108. Epub 2013 Aug 30. No abstract available. Erratum in: Eur Heart J. 2014 Jul 14;35(27):1824.

PMID:
23996285
37.

Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure.

Dahl CP, Aukrust P, Nymo SH, Kjekshus J, Cleland JG, McMurray JJ, Wikstrand J, Gullestad L, Ueland T.

Int J Cardiol. 2013 Oct 9;168(4):4427-9. doi: 10.1016/j.ijcard.2013.05.008. Epub 2013 May 26. No abstract available.

PMID:
23714594
38.

Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis.

Gravning J, Smedsrud MK, Omland T, Eek C, Skulstad H, Aaberge L, Bendz B, Kjekshus J, Mørkrid L, Edvardsen T.

Am Heart J. 2013 May;165(5):716-24. doi: 10.1016/j.ahj.2013.02.008. Epub 2013 Mar 26.

PMID:
23622908
39.

CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.

Ueland T, Nymo SH, Latini R, McMurray JJ, Kjekshus J, Yndestad A, Fucili A, Grosu A, Masson S, Maggioni AP, Gullestad L, Aukrust P; Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial; Investigators of the GISSI-Heart Failure (GISSI-HF) trial.

Eur J Heart Fail. 2013 Jul;15(7):747-55. doi: 10.1093/eurjhf/hft031. Epub 2013 Mar 13.

40.

Effect of rosuvastatin on fatigue in patients with heart failure.

Perez AC, Jhund P, Preiss D, Kjekshus J, McMurray JJ.

J Am Coll Cardiol. 2013 Mar 12;61(10):1121-2. doi: 10.1016/j.jacc.2012.12.004. No abstract available.

41.

Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, Yndestad A, Cleland JG, McMurray JJ, Aukrust P, Gullestad L.

Circ Heart Fail. 2013 Jan;6(1):91-8. doi: 10.1161/CIRCHEARTFAILURE.112.972653. Epub 2012 Dec 10.

PMID:
23230311
42.

Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT.

Inglis SC, Bebchuk J, Al-Suhaim SA, Case J, Pfeffer MA, Solomon SD, Hou YR, Pitt B, Dargie HJ, Ford I, Kjekshus J, Zannad F, Dickstein K, McMurray JJ.

Int J Cardiol. 2013 Sep 30;168(2):1094-101. doi: 10.1016/j.ijcard.2012.11.033. Epub 2012 Nov 26.

PMID:
23194780
43.

The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P.

Am Heart J. 2012 Dec;164(6):878-83. doi: 10.1016/j.ahj.2012.08.021. Epub 2012 Oct 29.

PMID:
23194488
44.

CT examination of the pericardium and lungs in helicopter pilots exposed to vibration and noise.

Kåsin JI, Kjellevand TO, Kjekshus J, Nesheim GB, Wagstaff A.

Aviat Space Environ Med. 2012 Sep;83(9):858-64.

PMID:
22946349
45.

Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.

Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ.

JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439.

PMID:
22910758
46.

Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Böhm M, van Veldhuisen DJ, Komajda M, Cleland JG, Wikstrand J, McMurray JJ, Aukrust P; CORONA Study Group.

Eur Heart J. 2012 Sep;33(18):2290-6. Epub 2012 Apr 17.

PMID:
22513778
47.

The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.

Yndestad A, Finsen AV, Ueland T, Husberg C, Dahl CP, Øie E, Vinge LE, Sjaastad I, Sandanger Ø, Ranheim T, Dickstein K, Kjekshus J, Damås JK, Fiane AE, Hilfiker-Kleiner D, Lipp M, Gullestad L, Christensen G, Aukrust P.

PLoS One. 2012;7(3):e33038. doi: 10.1371/journal.pone.0033038. Epub 2012 Mar 12.

48.

Importance and management of chronic sleep apnoea in cardiology.

Jaffe LM, Kjekshus J, Gottlieb SS.

Eur Heart J. 2013 Mar;34(11):809-15. doi: 10.1093/eurheartj/ehs046. Epub 2012 Mar 16. Review.

PMID:
22427382
49.

Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.

Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Cleland JG, Aukrust P, Gullestad L.

Eur J Heart Fail. 2012 Mar;14(3):268-77. doi: 10.1093/eurjhf/hfs006. Epub 2012 Feb 2.

50.

The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*.

Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L, Aukrust P, Yndestad A.

J Intern Med. 2012 May;271(5):436-43. doi: 10.1111/j.1365-2796.2011.02503.x. Epub 2012 Jan 16.

Supplemental Content

Loading ...
Support Center